Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Island Kinetics, Inc. d.b.a. CoValence Laboratories

US Class III Terminated · initiated 2026-03-18

Subpotent Drug

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-03-17

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufa…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-03-17

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufa…

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-03-17

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufa…

Chiesi USA, Inc.

US Class II Ongoing · initiated 2026-03-17

Lack of Assurance of Sterility

Viatris, Inc.

US Class II Ongoing · initiated 2026-03-17

Failed Dissolution Specifications

Nephron SC, LLC

US Class II Ongoing · initiated 2026-03-17

Labelling: Illegible label

Disinfectant Spray & Wipe Cleaner

Canada Type II Ongoing · initiated 2026-03-17

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concer…

Amerisource Health Services LLC

US Class II Ongoing · initiated 2026-03-16

Failed tablet specifications.

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-03-16

CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-03-16

CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-03-16

CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-03-13

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-03-13

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

ENDO USA, Inc.

US Class II Ongoing · initiated 2026-03-13

Crystallization; identified as Buprenorphine free base

Nitrous Oxide Chargers

Canada Type I Ongoing · initiated 2026-03-12

Product safety. Do not inhale nitrous oxide products for recreational purposes.Seek immediate medical attention from a health care professional (physician, nurs…

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility